Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia

Acta Haematologica

Volumn 102, Issue 3, 1999, Pages 115-123

  Kurotaki, Hidekachi ^a   Tsushima, Yaeko ^a   Nagai, Kazunori ^a   Yagihashi, Soroku ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Acute myelogenous leukemia; Apoptosis; bcl 2; Bone marrow; Immunohistochemistry; Myelodysplastic syndrome; p53; TUNEL

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW; CARCINOGENESIS; CELL COUNT; CELL TRANSFORMATION; CONTROLLED STUDY; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NICK END LABELING; PRIORITY JOURNAL;

EID: 0033387759     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040984     Document Type: Article

References (38)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51: 189-199.
2. Third MIC Cooperative Study Group: Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Cancer Genet Cytogenet 1988;32: 1-10.
3. Clark DM, Lampert IA: Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective haematopoiesis. Leuk Lymphoma 1990;2:415-418.
4. Yoshida Y: Hypothesis: Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993;7:144-146.
5. Raza A, Gezer S, Mundle S, Xue-Zhi G, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H: Apoptosis in bone marrow biopsy samples involving stroma and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86:268-276.
6. Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ: bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
7. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352:345-347.
8. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA, Della Porta G: bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992;79:1291-1298.
9. Jonveaux P, Fenaux P, Quiquandon I, Pignon JM, Laï JL, Loucheux-Lefebvre MH, Goossens M, Bauters F, Berger R: Mutation in the p53 gene in myelodysplastic syndromes. Oncogene 1991;6:2243-2247.
10. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H: Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993;81:3022-3026.
11. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
12. Cattoretti G, Pileri S, Parravicini C, Becker MHG, Poggi S, Bifulco C, Key G, D'Amato L, Sabattini E, Feudale E, Reynolds F, Gerdes J, Rilke F: Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993;171:83-98.
13. Harlow ED, Crawford LV, Pim DC, Williamson NM: Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol 1981; 39:861-869.
14. Hellström-Lindberg E, Kanter-Lewensohn L, Öst Å: Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997;21:415-425.
15. Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P: Is apoptosis a massive process in myelodysplastic syndrome? Br J Haematol 1996;95:386-371.
16. Arends MJ, Wyllie AH: Apoptosis: Mechanism and roles in pathology. Int Rev Exp Pathol 1991;32:223-254.
17. Duke RC, Chervenak R, Cohen JJ: Endogenous endonuclease-induced DNA fragmentation: An early event in cell mediated cytolysis. Proc Natl Acad Sci USA 1983;80:6361-6365.
18. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
19. Carson DA, Ribeiro JM: Apoptosis and disease. Lancet 1993;341:1251-1254.
20. Hockenbery DM, Zutter M, Hickey W, Nahm M. Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-6965.
21. Davis RE, Greenberg PL: bcl-2 expression by myeloid precursors in myelodysplastic syndromes: Relation to disease progression. Leuk Res 1998;22:767-777.
22. Kitagawa M, Yoshida S, Kuwata T, Tanizawa T, Kamiyama R: p53 expression in myeloid cells of myelodysplastic syndromes: Association with evolution of overt leukemia. Am J Pathol 1994;145:338-344.
23. Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, Goldman J, Zaccharia A, Berrebi A, Canaani E: p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 1991;88:6293-6297.
24. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerchaert JP: p53 gene mutation in acute myeloid leukemia with 17p monosomy. Blood 1991;78:1652-1657.
25. Slingerland JM, Minden MD, Benchimol S: Mutations of the p53 gene in human acute myelogenous leukemia. Blood 1991;77:1500-1507.
26. Gaidano G, Guerrasio A, Serra A, Carozzi F, Rege-Cambrin G, Petroni D, Saglio G: Mutation in the p53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. Leukemia 1993;7:946-953.
27. Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K: Frequent p53 gene mutations in blast crisis myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 1992;52:6588-6593.
28. Avigad S, Barel D, Blau O, Malka A, Zoldan M, Mor C, Fogel M, Cohen IJ, Stark B, Goshen Y, Stein J, Zaizov R: A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 1997;14:1541-1545.
29. Louis DN, Rubio MP, Correa KM, Gusella JF, von Deimling A: Molecular genetics of pediatric brain stem gliomas. Applicaiton of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol 1993;52: 507-515.
30. Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P: Radical disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 1995;55:1485-1490.
31. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995;10:1217-1227.
32. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690-694.
33. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzitti M, Di Fronzo G, Rilke F. Veronesi U: The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
34. Piris MA, Pezalla F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R, Rilke F: p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 1994;69:337-341.
35. Martin HM, Filipe MI, Morris RW, Lane DP, Silverstre F: p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859-862.
36. Starzynska T, Bromley M, Gosh A, Stern PL: Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-562.
37. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992;52:4828-4831.
38. Marin MC, Hsu B, Meyn RE, Donehower LA, el-Naggar AK, McDonnell TJ: Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 1994;9:3107-3112.